Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 2/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4137213 | 0.83 | STS (0.39) | STSDDR1MAPTCYP2D6TSHR | |
| SCHEMBL4131317 | 0.76 | STS (0.56) | STSMAPT | |
| SCHEMBL4738498 | 0.75 | EPHX2 (0.38) | USP2 | |
| SCHEMBL4131320 | 0.74 | STS (0.42) | STSDDR1KCNH2CACNA1ILMNA | |
| SCHEMBL14528538 | 0.73 | CES2 (0.47) | STSLMNAPSEN1PSEN2APH1B | |
| SCHEMBL2916404 | 0.67 | STS (0.55) | STSMAPTPSEN1PSEN2APH1B | |
| SCHEMBL2920158 | 0.66 | STS (0.62) | STSKCNH2CACNA1IPKM | |
| SCHEMBL2385073 | 0.66 | POLB (0.55) | USP2CYP3A4CYP2C9MAPTLMNA | |
| SCHEMBL2921629 | 0.65 | STS (0.53) | STSCYP3A4MAPTCYP2D6TSHR | |
| SCHEMBL13979562 | 0.64 | GAA (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042899-A1 | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | LEHR PHILIPP | 2009-02-12 | — | — | US | disclosed |
| US-7439362-B2 | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2008-10-21 | — | — | US | disclosed |
| US-20060052393-A1 | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2006-03-09 | — | — | US | disclosed |
| EP-1492782-A1 | PIPERAZINYL- OR PIPERIDINYLAMINE-SULFAMIC ACID AMIDES AS INHIBITORS OF STEROID SULFATASE | Novartis AG (CH) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082842-A1 | PIPERAZINYL- OR PIPERIDINYLAMINE-SULFAMIC ACID AMIDES AS INHIBITORS OF STEROID SULFATASE | NOVARTIS AG (CH) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042899-A1 | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | STS, SULT2A1, ARSA | STS 1/4885DDR1 3648/4885KCNH2 4569/4885 |
| US-20060052393-A1 | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | STS, SELENOI, SULT2A1 | STS 1/4885DDR1 4410/4885KCNH2 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.